Medigen Vaccine Biologics (6547) - Net Assets
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has net assets worth NT$3.56 Billion TWD (≈ $112.01 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.76 Billion ≈ $149.99 Million USD) and total liabilities (NT$1.21 Billion ≈ $37.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 6547 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.56 Billion |
| % of Total Assets | 74.68% |
| Annual Growth Rate | 28.92% |
| 5-Year Change | -25.59% |
| 10-Year Change | 136.76% |
| Growth Volatility | 78.61 |
Medigen Vaccine Biologics - Net Assets Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Medigen Vaccine Biologics stock valuation.
Annual Net Assets for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual net assets of Medigen Vaccine Biologics from 2012 to 2025. Also explore Medigen Vaccine Biologics (6547) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.48 Billion ≈ $109.62 Million |
-9.63% |
| 2024-12-31 | NT$3.85 Billion ≈ $121.30 Million |
+0.09% |
| 2023-12-31 | NT$3.85 Billion ≈ $121.19 Million |
-23.51% |
| 2022-12-31 | NT$5.03 Billion ≈ $158.44 Million |
+7.55% |
| 2021-12-31 | NT$4.68 Billion ≈ $147.32 Million |
+48.85% |
| 2020-12-31 | NT$3.14 Billion ≈ $98.97 Million |
+129.84% |
| 2019-12-31 | NT$1.37 Billion ≈ $43.06 Million |
-15.22% |
| 2018-12-31 | NT$1.61 Billion ≈ $50.79 Million |
+5.98% |
| 2017-12-31 | NT$1.52 Billion ≈ $47.92 Million |
+3.51% |
| 2016-12-31 | NT$1.47 Billion ≈ $46.30 Million |
+9.31% |
| 2015-12-31 | NT$1.34 Billion ≈ $42.35 Million |
+24.62% |
| 2014-12-31 | NT$1.08 Billion ≈ $33.99 Million |
+135.56% |
| 2013-12-31 | NT$457.94 Million ≈ $14.43 Million |
+257.76% |
| 2012-12-31 | NT$128.00 Million ≈ $4.03 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medigen Vaccine Biologics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25971400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$3.76 Billion | 108.10% |
| Total Equity | NT$3.48 Billion | 100.00% |
Medigen Vaccine Biologics Competitors by Market Cap
The table below lists competitors of Medigen Vaccine Biologics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enovix Corp
NASDAQ:ENVX
|
$619.39 Million |
|
Zhongbai Holdings Group Co Ltd
SHE:000759
|
$619.44 Million |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
$619.59 Million |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
$619.68 Million |
|
Envela Corp
NYSE MKT:ELA
|
$619.23 Million |
|
Luyan Pharma Co Ltd
SHE:002788
|
$619.12 Million |
|
Haoxiangni Jujube Co Ltd
SHE:002582
|
$619.10 Million |
|
Ciputra Development Tbk
JK:CTRA
|
$619.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medigen Vaccine Biologics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,849,987,000 to 3,479,264,000, a change of -370,723,000 (-9.6%).
- Net loss of 281,714,000 reduced equity.
- Other factors decreased equity by 89,009,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-281.71 Million | -8.1% |
| Other Changes | NT$-89.01 Million | -2.56% |
| Total Change | NT$- | -9.63% |
Book Value vs Market Value Analysis
This analysis compares Medigen Vaccine Biologics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.85x to 5.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | NT$15.52 | NT$59.80 | x |
| 2013-12-31 | NT$18.73 | NT$59.80 | x |
| 2014-12-31 | NT$10.66 | NT$59.80 | x |
| 2015-12-31 | NT$9.51 | NT$59.80 | x |
| 2016-12-31 | NT$8.40 | NT$59.80 | x |
| 2017-12-31 | NT$7.70 | NT$59.80 | x |
| 2018-12-31 | NT$7.06 | NT$59.80 | x |
| 2019-12-31 | NT$5.78 | NT$59.80 | x |
| 2020-12-31 | NT$11.29 | NT$59.80 | x |
| 2021-12-31 | NT$14.65 | NT$59.80 | x |
| 2022-12-31 | NT$15.55 | NT$59.80 | x |
| 2023-12-31 | NT$11.72 | NT$59.80 | x |
| 2024-12-31 | NT$11.71 | NT$59.80 | x |
| 2025-12-31 | NT$10.58 | NT$59.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medigen Vaccine Biologics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -45.94%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.13x
- Recent ROE (-8.10%) is above the historical average (-16.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -17.19% | 0.00% | 0.00x | 1.17x | NT$-34.80 Million |
| 2013 | -16.77% | 0.00% | 0.00x | 1.04x | NT$-122.60 Million |
| 2014 | -9.77% | 0.00% | 0.00x | 1.13x | NT$-213.28 Million |
| 2015 | -13.52% | 0.00% | 0.00x | 1.23x | NT$-316.16 Million |
| 2016 | -14.26% | 0.00% | 0.00x | 1.24x | NT$-356.53 Million |
| 2017 | -22.37% | 0.00% | 0.00x | 1.40x | NT$-492.40 Million |
| 2018 | -29.55% | 0.00% | 0.00x | 1.35x | NT$-637.55 Million |
| 2019 | -46.59% | -56861.07% | 0.00x | 1.67x | NT$-773.52 Million |
| 2020 | -21.99% | -6002.42% | 0.00x | 1.11x | NT$-1.00 Billion |
| 2021 | 30.16% | 42.98% | 0.62x | 1.13x | NT$942.65 Million |
| 2022 | -29.86% | -411.31% | 0.05x | 1.46x | NT$-2.00 Billion |
| 2023 | -30.15% | -297.68% | 0.06x | 1.58x | NT$-1.54 Billion |
| 2024 | -2.09% | -13.29% | 0.14x | 1.13x | NT$-465.46 Million |
| 2025 | -8.10% | -45.94% | 0.16x | 1.13x | NT$-629.64 Million |
Industry Comparison
This section compares Medigen Vaccine Biologics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,816,542,400
- Average return on equity (ROE) among peers: 3.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medigen Vaccine Biologics (6547) | NT$3.56 Billion | -17.19% | 0.34x | $619.37 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $95.41 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $4.08 Billion | 4.01% | 0.58x | $192.35 Million |
| Panion & BF Biotech Inc (1760) | $656.55 Million | 2.76% | 0.52x | $145.06 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.71 Billion | 5.66% | 0.78x | $81.67 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $104.38 Million |
| Level Biotechnology (3118) | $544.84 Million | 12.51% | 0.45x | $31.54 Million |
| GenMont Biotech Inc (3164) | $1.45 Billion | 3.95% | 0.15x | $44.17 Million |
| Medigen Biotechnology (3176) | $5.04 Billion | -4.06% | 0.33x | $165.68 Million |
| Sagittarius Life Science (3205) | $455.42 Million | -16.29% | 0.27x | $99.91 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $115.03 Million |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more